Pfizer is deepening its already long-term investment and partnership strategy with UK-based biotech Mission Therapeutics and its work on selectively inhibiting deubiquitylating enzymes (DUBs).

Pfizer’s VC arm, Pfizer Ventures, has led a new $15 million (£12 million) round in the Cambridge, UK, company while also boosting the relationship by “entering into an evaluation and option agreement for DUB target validation.” Mission now has just over $100 million in funding to date. Source: Fierce Biotech 6/7/2020